The first Phase III and second Phase III trials will be multi-centre, randomised, assessor-blind, active-comparator studies to determine the efficacy, safety and tolerability of orally administered Zintrodiazine
Outlines 1,500-member internal cadre, digital regulatory system, and faster SEC-led reviews
The announcement marks Dr. Reddy’s Day?1 entry into the GLP?1 receptor agonists therapy space and readiness to serve patients in India
Company to launch product after the expiry of semaglutide patent in India
Globally, BRUKINSA is approved in more than 70 countries
The market size of Aspart in India is currently estimated over Rs. 260 crore with only 2 players
DCGI has also granted permission to manufacture and market FDF of Cefepime and Enmetazobactam as a dry powder injectable
The approval allows treatment of heart failure patients irrespective of the ejection fraction based on new trial DELIVER conducted by AstraZeneca
Themis will market this drug with the brand name REMITHEM.
Lynparza is the first and only approved PARPi targeting BRCA-mutated HER2-negative high-risk early breast cancer
Subscribe To Our Newsletter & Stay Updated
